...
首页> 外文期刊>Biomaterials >Enhancement of cell recognition in vitro by dual-ligand cancer targeting gold nanoparticles.
【24h】

Enhancement of cell recognition in vitro by dual-ligand cancer targeting gold nanoparticles.

机译:靶向金纳米颗粒的双配体癌症在体外增强细胞识别。

获取原文
获取原文并翻译 | 示例

摘要

A dual-ligand gold nanoparticle (DLGNP) was designed and synthesized to explore the therapeutic benefits of multivalent interactions between gold nanoparticles (GNPs) and cancer cells. DLGNP was tested on human epidermal cancer cells (KB), which had high expression of folate receptor. The cellular uptake of DLGNP was increased by 3.9 and 12.7 folds compared with GNP-folate or GNP-glucose. The enhanced cell recognition was due to multivalent interactions between both ligands on GNPs and cancer cells as shown by the ligand competition experiments. Furthermore, the multivalent interactions increased contrast between cells with high and low expression of folate receptors. The enhanced cell recognition enabled DLGNP to kill KB cells under X-ray irradiation at a dose that was safe to folate receptor low-expression (such as normal) cells. Thus DLGNP has the potential to be a cancer-specific nano-theranostic agent.
机译:设计并合成了双配体金纳米颗粒(DLGNP),以探索金纳米颗粒(GNP)与癌细胞之间多价相互作用的治疗益处。在具有高叶酸受体表达的人表皮癌细胞(KB)上测试了DLGNP。与GNP叶酸或GNP葡萄糖相比,DLGNP的细胞摄取增加了3.9倍和12.7倍。如配体竞争实验所示,增强的细胞识别是由于GNP上两个配体与癌细胞之间的多价相互作用。此外,多价相互作用增加了具有高和低叶酸受体表达的细胞之间的对比度。增强的细胞识别能力使DLGNP在X射线照射下可以安全地叶酸受体低表达(如正常)细胞剂量杀死KB细胞。因此,DLGNP有可能成为癌症特异性的纳米治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号